Table 4.

Summary of preferred treatment option recommendations in the empiric therapy of meropenem for different types of infection based on our analysis.

Optimal PD target	Corresponding types of infection or infected sites	Preferred treatment option recommendations for MNBSs with MICs ≥16 mg/L
50% fT > MIC	Bacterial peritonitis or intraabdominal infections, bloodstream infections, skin and soft tissue infections, or urinary tract infections	2 g [1.5 g (5-min IVB) + 0.5 g (6 h)] q 8 h or 1.5 g [(5-min IVB) + 0.5 g (6 h)] q 6 h
50% fT > 2 × MIC	Bacterial hepatitis, metritis, oophoritis, proctitis, or prostatitis	2 g [1.5 g (5-min IVB) + 0.5 g (6 h)] q 8 h or 1.5 g [1 g (5-min IVB) + 0.5 g (6 h)] q 6 h
50% fT > 5 × MIC	LRTIs, such as pneumonia, bronchitis, or pleural infections	2 g [1.5 g (5-min IVB) + 0.5 g (5 h)] q 8 h